Cel Sci (CVM) Operating Leases (2016 - 2026)
Cel Sci (CVM) posted Operating Leases of $1.5 million for Q1 2026, down 3.61% sequentially from $1.5 million in Q4 2025, and up 9.8% YoY from $1.3 million in Q1 2025.
Cel Sci (CVM) Operating Leases (2016 - 2026) Analysis & Trends
Cel Sci has reported Operating Leases for 11 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Operating Leases rose 9.8% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 9.8% YoY) and the FY2025 annual result came in at $1.3 million, down 54.25% from the prior year.
- Operating Leases retreated to $1.5 million in Q1 2026 per CVM's latest filing, from $1.5 million in the prior quarter.
- Over five years, Operating Leases peaked at $3.9 million in Q3 2022 and troughed at $190000.0 in Q1 2023.
- A 5-year average of $1.8 million and a median of $1.5 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases tumbled 90.95% in 2023, then jumped 712.7% in 2024.
- Over 5 years, Operating Leases stood at $2.0 million in 2022, then declined by 20.03% to $1.6 million in 2023, then fell by 14.14% to $1.4 million in 2024, then climbed by 10.9% to $1.5 million in 2025, then slipped by 3.61% to $1.5 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $1.5 million, $1.5 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 1.49 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 2.75 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.60 Mn |
| Sep 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 1.90 Mn |
| Mar 31, 2023 | 190,000.00 |
| Dec 31, 2022 | 2.00 Mn |
| Sep 30, 2022 | 3.87 Mn |
| Jun 30, 2022 | 2.10 Mn |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 2.02 Mn |
| Jun 30, 2021 | 1.10 Mn |